Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
imMUno
1 other identifier
observational
100
1 country
1
Brief Summary
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2016
CompletedFirst Submitted
Initial submission to the registry
July 12, 2017
CompletedFirst Posted
Study publicly available on registry
May 28, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedAugust 11, 2025
August 1, 2025
3 years
July 12, 2017
August 7, 2025
Conditions
Outcome Measures
Primary Outcomes (5)
Response rate Data collection of the efficacity of PD-1 inhibitors
Description of Response rate
December 2019
Progression Free Survival Data collection of the efficacity of PD-1 inhibitors
Description of PFS (Progression Free Survival)
December 2019
Global Survival Data collection of the efficacity of PD-1 inhibitors
Description of Global Survival
December 2019
Stability Data collection of the efficacity of PD-1 inhibitors
Description of Stability at 6 months
December 2019
Objective response Data collection of the efficacity of PD-1 inhibitors
Description of Objective response
December 2019
Secondary Outcomes (1)
Exploration of PD-1 inhibitors biomarkers
December 2019
Eligibility Criteria
Patients with metastatic uveal melanoma.
You may qualify if:
- Patients with metastatic uveal melanoma
- Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment
You may not qualify if:
- Antecedent of another evolutionary tumor pathology
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institut Curielead
Study Sites (1)
Rodrigues
Paris, Île-de-France Region, 75005, France
Related Publications (1)
Saint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, Penel N, Kurtz JE, Le Corre Y, Dutriaux C, Gardrat S, Barnhill R, Matet A, Cassoux N, Houy A, Ramtohul T, Servois V, Mariani P, Piperno-Neumann S, Stern MH, Rodrigues M. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. Eur J Cancer. 2022 Sep;173:105-112. doi: 10.1016/j.ejca.2022.06.033. Epub 2022 Jul 19.
PMID: 35863105RESULT
Biospecimen
Biocollection of tumoral tissues
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Manuel Rodrigues, MD
Institut Curie
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 12, 2017
First Posted
May 28, 2019
Study Start
November 1, 2016
Primary Completion
November 1, 2019
Study Completion
December 1, 2020
Last Updated
August 11, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share